No profile data available.
Bionano Genomics, Inc. (BNGO) is a healthcare company in the biological analysis equipment industry, based in San Diego, United States, with about 95 full-time employees.
It reported revenue of $30.78 million for fiscal year 2024, down 14.8% from fiscal year 2023, and net income of -$112.02 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $7.37 million, up 21.3% from a year before. Europe, The Middle East and Africa was its largest region in fiscal year 2025, with 49% of revenue. Its market capitalization was $16.90 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia.
Bionano Genomics reported $30.78 million in revenue for fiscal year 2024, down 14.8% from $36.12 million in fiscal year 2023. In Q3 2025 revenue was $7.37 million.
Europe, The Middle East and Africa: 49% of revenue by region in fiscal year 2025, followed by Americas (27%).
$16.90 million as of October 9, 2026.
Listed companies of a similar size in the same industry (biological analysis equipment) include Seer, Inc. (SEER), INmune Bio, Inc. (INMB), Rapid Micro Biosystems, Inc. (RPID), Advanced Biomed Inc. (ADVB).